Condition
Arsenic Trioxide
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 4 (1)
Trial Status
Recruiting2
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06778187Phase 2Recruiting
Oral-ATO for TP53-mutated Myeloid Malignancies
NCT05682131Phase 4RecruitingPrimary
South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol
NCT04695223Phase 2UnknownPrimary
Arsenic Trioxide for Structural p53 Mutations
Showing all 3 trials